Format

Send to

Choose Destination
Clin Infect Dis. 2017 Feb 1;64(3):295-300. doi: 10.1093/cid/ciw737. Epub 2016 Nov 12.

Therapeutic Immune Recovery and Reduction of CXCR4-Tropic HIV-1.

Author information

1
Molecular Virology, Department of Biomedicine-Petersplatz, University of Basel.
2
Institute for Immunogenetics, Kaiserslautern, and.
3
Swiss HIV Cohort Study Data Center, University Hospital Lausanne.
4
Institute of Medical Virology, National Center for Retroviruses, University of Zürich.
5
Institute for Infectious Diseases, University of Berne.
6
Department of Microbiology, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
7
Max Planck Institute for Informatics, Saarbrücken, Germany.
8
Molecular Virology, Department of Biomedicine-Petersplatz, University of Basel, thomas.klimkait@unibas.ch.

Abstract

BACKGROUND:

In the absence of therapy, CXCR4 (X4)-tropic human immunodeficiency virus type 1 (HIV-1) increases over time, associated with accelerated disease progression. In contrast, the majority of patients receiving long-term combination antiretroviral therapy (cART) present with CCR5 (R5)-tropic HIV-1 variants. It is unclear whether cART itself mediates the reduction of X4-tropic HIV-1. The current study aimed at assessing the tropism of viral integrates in patients' blood during fully suppressive cART.

METHODS:

The relative frequencies of X4-tropic proviral HIV-1 variants were determined by means of next-generation sequencing (False Positive Rate (FPR), 3.5%; R5- or X4 tropic variants occurring at less than 2% of the total virus population) for 35 treated patients in the Swiss HIV Cohort Study and followed longitudinally over time. Full viral suppression and a continuous CD4 T-cell recovery during cART were documented for all patients. Viral phylogenetic changes and sequence evolution were analyzed.

RESULTS:

The majority of patients (80%) experienced no frequency increase in X4-tropic proviruses during therapy. Although some proviral sequence evolution was demonstrable in >50% of these patients during therapy, this growing viral diversity was in no case paralleled by the emergence or expansion of X4-tropic provirus variants. In the remaining 20% of patients, the documented expansion of X4-tropic provirus was based on the outgrowth of single viral variants from minority populations already present before therapy initiation.

CONCLUSION:

Our study demonstrates that X4-tropic HIV sharply declines in most patients during successful therapy, which indicates a preferential tropism-dependent provirus elimination in the immunocompetent host. The recently implemented World Health Organization strategies of immediate therapy initiation are fully in line with this gradual loss of X4 tropism during therapy. Moreover, the early use of coreceptor antagonists against the remaining CCR5-tropic viruses may be indicated.

KEYWORDS:

CXCR4-tropic; HIV; immune system.; tropism

PMID:
27838645
DOI:
10.1093/cid/ciw737
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center